top of page
Browse by category
Search
GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour
Patients on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Victoza (Liraglutide 1.8mg), Saxenda (Liraglutide 3mg), Ozempic...
European Medicines Agency to discuss anaesthesia risk for weight-loss drugs
The European Medicines Agency (EMA) will assess the risk that patients on weight loss drugs such as semaglutide and tirzepatide may...
Saxenda approved for the treatment of obesity in adolescents
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a licence extension for Saxenda (Novo Nordisk) for the...
FDA approves Saxenda for the treatment of obesity in adolescents
Novo Nordisk has received FDA approval for an updated label for Saxenda (liraglutide) injection 3mg for use in the treatment of obesity...
Browse by tag
bottom of page